Holen Sie sich die Stockscreener-App
4.45
3.68%
-0.17
Handel nachbörslich:
4.40
-0.05
-1.12%
Schlusskurs vom Vortag:
$4.62
Offen:
$4.62
24-Stunden-Volumen:
156.22K
Relative Volume:
1.07
Marktkapitalisierung:
$179.99M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$63.21M
KGV:
2.996
EPS:
1.4853
Netto-Cashflow:
$-9.71M
1W Leistung:
+11.81%
1M Leistung:
+26.06%
6M Leistung:
+80.16%
1J Leistung:
+98.66%
1-Tages-Spanne:
$4.35
$4.62
1-Wochen-Bereich:
$3.83
$5.01
52-Wochen-Spanne:
$1.975
$5.01
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.45 | 186.86M | 2.00M | 63.21M | -9.71M | 1.4853 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Oramed Pharmaceuticals stock (US68403P1003): Shares surged 7.98% to $2.30 - AD HOC NEWS
TradingKey - TradingKey
MSN Money - MSN
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
NNDM stock in focus: Nano Dimension pops a poison pill days after Oramed stake build-up - MSN
ORMP Should I Buy - Intellectia AI
ORMP (Oramed Pharmaceuticals) falls 2.84% after releasing Q4 2025 earnings with no prior analyst consensus estimates.Current Ratio - Xã Thanh Hà
ORMP (Oramed Pharmaceuticals Inc.) rises 0.53 percent following release of its 2025 fourth quarter earnings results.Debt/Equity - Xã Thanh Hà
Oramed Pharmaceuticals (ORMP) Stock Rally Stalls (+1.05%) 2026-04-16Shared Momentum Picks - Xã Vĩnh Công
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors - Yahoo Finance
Evolus and Oramed Pharmaceuticals Compared - National Today
Setup Watch: Is Oramed Pharmaceuticals Inc stock technically oversold2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Sell Signal: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Overview Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Fund Flows: Can Oramed Pharmaceuticals Inc keep up with sector leadersMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Technical Analysis: Will Oramed Pharmaceuticals Inc face regulatory challenges2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Lifeward scoops US$20M after completing Oratech Pharma takeover - Mugglehead Investment Magazine
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
ORMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Oramed Pharmaceuticals stock: Oral insulin pioneer or high-risk bet? - AD HOC NEWS
INO Stock Analysis: Inovio Pharmaceuticals Inc. plunges 35% to $1.13 biotech support level - Xã Thanh Hà
ORMP Q4 Earnings: Beats Estimates by $1.16 - newser.com
Oramed Completes Oratech Sale and Strategic Lifeward Financing - The Globe and Mail
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oramed (ORMP) completes Oratech sale and buys $9M Lifeward notes - Stock Titan
Oramed (NASDAQ: ORMP) CSO uses 435,084 shares to cover RSU tax - Stock Titan
Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding - Stock Titan
FOMO Trade: Is Oramed Pharmaceuticals Inc stock good for income investorsMarket Sentiment Report & Entry and Exit Point Strategies - baoquankhu1.vn
Oramed Pharmaceuticals Hits New 52-Week High of $3.76, Up 75% Yearly - Markets Mojo
Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38 - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Oramed Pharmaceuticals: Oral Insulin Technology, Strategic Investments, and 2026 Business Overview - Minichart
Oramed: Q4 Earnings Snapshot - Barchart.com
Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS - TradingView — Track All Markets
Oramed (NASDAQ: ORMP) pivots with Lifeward deal and Alpha Tau stake - Stock Titan
Lifeward closes Oramed partnership, secures $10 million funding By Investing.com - Investing.com Australia
Lifeward Closes Oramed Partnership, Acquires Oratech Pharma - Moomoo
Lifeward closes Oramed partnership, secures $10 million funding - Investing.com
Lifeward Successfully Closes on Strategic Partnership with Oramed - manilatimes.net
Lifeward Ltd. completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc.. - marketscreener.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Oramed Pharmaceuticals Inc expected to post breakeven results a shareEarnings Preview - TradingView
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):